| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
British Medical Bulletin 56:1019-1036 (2000)
© 2000 The British Council
research-article |
Specific immunotherapy
Allergy & Clinical Immunology, Imperial College School of medicine, National Heart and Lung Institute London, UK
Correspondence to: Dr Mark Larché, Allergy & Clinical Immunology, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London Sw3 6LY,UK
Abstract
The prevalence of atopic allaergic disease increased subtantially towards the end of the 20th century and is set to rise further. This group of diseases now constitutes the most common cause of choric ill health in industrialised countries. Despite considerable attention from the pharmaceutical industry, little progress has been made in the development of disease-modifying therapies. In contrast, recent activity has focused almost exclusively on treatment of symptoms (palliation)rather than cause. The failure of palliative approaches to address the issue of increasing incidence of disease-modifying therapy is specific allergen immunotherapy (SIT) in which increasing doses of whole allergen extract are administrered in increasing dose in order to desensities the allergic subject.